Redmond Asset Management LLC Lowers Position in Bio-Techne Corp (TECH)

Redmond Asset Management LLC decreased its stake in Bio-Techne Corp (NASDAQ:TECH) by 0.5% during the fourth quarter, Holdings Channel reports. The firm owned 15,397 shares of the company’s stock after selling 70 shares during the period. Redmond Asset Management LLC’s holdings in Bio-Techne Corp were worth $1,583,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. O Shaughnessy Asset Management LLC raised its position in shares of Bio-Techne Corp by 7.7% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,092 shares of the company’s stock valued at $112,000 after buying an additional 78 shares during the period. LS Investment Advisors LLC raised its position in shares of Bio-Techne Corp by 14.6% in the third quarter. LS Investment Advisors LLC now owns 1,042 shares of the company’s stock valued at $114,000 after buying an additional 133 shares during the period. World Asset Management Inc raised its position in shares of Bio-Techne Corp by 33.3% in the third quarter. World Asset Management Inc now owns 2,417 shares of the company’s stock valued at $265,000 after buying an additional 604 shares during the period. Coldstream Capital Management Inc. raised its position in shares of Bio-Techne Corp by 55.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 4,658 shares of the company’s stock valued at $479,000 after buying an additional 1,658 shares during the period. Finally, Wasatch Advisors Inc. raised its position in shares of Bio-Techne Corp by 8.9% in the third quarter. Wasatch Advisors Inc. now owns 6,724 shares of the company’s stock valued at $736,000 after buying an additional 547 shares during the period. Institutional investors own 94.74% of the company’s stock.

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Shares of Bio-Techne Corp (NASDAQ:TECH) traded up 0.64% during mid-day trading on Monday, reaching $103.91. 264,609 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $101.46 and its 200-day moving average is $105.50. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of 49.53 and a beta of 0.73. Bio-Techne Corp has a 52-week low of $83.10 and a 52-week high of $117.42.

Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by $0.04. The business had revenue of $131.80 million for the quarter, compared to the consensus estimate of $134.74 million. Bio-Techne Corp had a return on equity of 13.95% and a net margin of 14.87%. Bio-Techne Corp’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.88 earnings per share. On average, equities analysts expect that Bio-Techne Corp will post $3.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Shareholders of record on Friday, February 17th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Wednesday, February 15th. Bio-Techne Corp’s payout ratio is 60.95%.

This report was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this report can be read at http://sleekmoney.com/redmond-asset-management-llc-lowers-position-in-bio-techne-corp-tech/1659141.html.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Bio-Techne Corp from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. Citigroup Inc. assumed coverage on shares of Bio-Techne Corp in a research note on Thursday. They set a “buy” rating and a $115.00 price target on the stock. Leerink Swann assumed coverage on shares of Bio-Techne Corp in a report on Thursday, November 10th. They set an “outperform” rating and a $122.00 price objective for the company. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $115.00 price objective on shares of Bio-Techne Corp in a report on Wednesday, January 18th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $119.00.

In other Bio-Techne Corp news, Director Karen A. Holbrook sold 1,000 shares of the stock in a transaction that occurred on Tuesday, November 29th. The stock was sold at an average price of $106.73, for a total transaction of $106,730.00. Following the transaction, the director now directly owns 1,973 shares in the company, valued at approximately $210,578.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 1,200 shares of company stock worth $127,662 over the last 90 days. Company insiders own 2.70% of the company’s stock.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

5 Day Chart for NASDAQ:TECH

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/redmond-asset-management-llc-lowers-position-in-bio-techne-corp-tech/1659141.html

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *